Biopharma Co. Juno Seeks IPO To Expand Cancer Drug R&D
Juno Therapeutics Inc. filed with the U.S. Securities and Exchange Commission on Monday for an up to $150 million initial public offering as the biopharmaceutical startup seeks to ramp up development...To view the full article, register now.
Already a subscriber? Click here to view full article